Journal article
Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS
A Svedbom, F Borgstöm, E Hernlund, O Ström, V Alekna, ML Bianchi, P Clark, MD Curiel, HP Dimai, M Jürisson, R Kallikorm, M Lember, O Lesnyak, E McCloskey, KM Sanders, S Silverman, A Solodovnikov, M Tamulaitiene, T Thomas, N Toroptsova Show all
Osteoporosis International | SPRINGER LONDON LTD | Published : 2018
Abstract
Summary: This study used data from the International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) to estimate the quality of life (QoL) impact of fracture. Hip, vertebral, and distal forearm fractures incur substantial QoL losses. Hip and vertebral fracture results in markedly impaired QoL for at least 18 months. Introduction: The International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) is a multinational observational study that aims to describe costs and quality of life (QoL) consequences of osteoporotic fractures. To date, 11 countries have participated in the study: Australia, Austria, Estonia, France, Italy, Lithuania, Mexico, Russia, Sp..
View full abstractGrants
Awarded by Amgen
Funding Acknowledgements
We are grateful to the Quality of Life and Epidemiology Working Group of the Committee of Scientific Advisors for the International Osteoporosis Foundation under whose supervision this study was undertaken. On its international level, the ICUROS is sponsored by Amgen, Eli Lilly, Medtronic, Novartis, Sanofi-Aventis, Servier, and Pfizer. In Australia, the study is supported by project grant no. 628422 from the National Health and Medical Research Council. In Austria, the study is sponsored by Central Association of Austrian Social Security Institution (Hauptverband der osterreichischen Sozialversicherungstrager), Austrian Society for Bone and Mineral Research (AuSBMR), Merck Sharp & Dohme, Servier GmbH, Medtronic GmbH, Amgen GmbH, Novartis GmbH, Nycomed GmbH, Roche GmbH, Sanofi-Aventis GmbH, and Daiichi-Sankyo GmbH. In France, we would like to thank Prs Bernard Cortet, Roland Chapurlat, Patrice Fardellone, Philippe Orcel, and Christian Roux for their work. In Mexico, the study was supported by CONACyT grant no. El 2008-01-87106, and we are grateful to Gabriela Chico, Master Student, Mexico City and Fernando Carlos, MHE, Mexico City. In Lithuania, the work was supported by National Osteoporosis Center, and gratitude is extended to Dr. Violeta Sinkeviciene and Inga Tamulaityte-Morozoviene (Faculty of Medicine of Vilnius University) for skillful technical assistance. In Russia, the following team members provided valuable contributions to the study: Dr. Oxana Nikitinskaya, Dr. Olga Dobrovolskaya (Institute of Rheumatology, RAS, Moscow), Prof. Larissa Menshikova, Dr. Julia Varavko (Medical Institute of Postgraduate Training, Irkutsk), Prof. Olga Ershova, Dr. Ksenia Belova (Yaroslavl State Medical University, Yaroslavl), Dr. Ksenia Usenko (Ural State Medical University, Yekaterinburg), Prof. Georgij Golubev, Dr. Vyacheslav Grebenshikov (Rostov-on-Don State Medical University, Rostov-on-Don), Prof. Eugenij Zotkin, Dr. Irina Zubkova (North-West Mechnikov State Medical University, Saint-Petersburg), Prof. Alexander Kochish, Dr. Sergej Ivanov (Vreden Institute of Traumatology and Orthopedics, Saint-Petersburg), and Dr. Radik Nurligayanov (City Clinical Hospital #21, Ufa). In the USA, Amgen Inc., Ingenix Pharmaceutical Services, Eli Lilly and Company, Medtronic Spine LLC, and Pfizer Inc. sponsored the study. Hoffmann La Roche and Amgen provided support. In Estonia, the study was supported by Estonian Science Foundation grant no. 9368. The global study team would like to thank Ingrid Lekander, Erik Landfeldt, Martin Kleman, Moa Ivergard, and Viktor Wintzell for contributing to the study. The following investigators provided valuable contributions to the Australian substudy: Prof JJ Watts and Professors GC Nicholson, E Seeman, R Prince, G Duque, T Winzenberg, L March, and PR Ebeling.